solo titoli da +100% parte 4

  • Ecco la 56° Edizione del settimanale "Le opportunità di Borsa" dedicato ai consulenti finanziari ed esperti di borsa.

    Settimana da incorniciare per i principali indici internazionali grazie alla trimestrale più attesa dell’anno che non ha deluso le aspettative. Nvidia negli ultimi tre mesi del 2023 ha generato ricavi superiori all’intero 2021, confermando la crescita da record della società grazie agli investimenti globali nell’intelligenza artificiale. I mercati azionari hanno festeggiato aggiornando i record assoluti a Wall Street e in Europa, mentre il Nikkei giapponese raggiunge un nuovo massimo storico dopo 34 anni. Le prossime mosse delle banche centrali rimangono sempre al centro dell’attenzione. Per continuare a leggere visita il link

ecco il grafico di sofo indicato da palm beach
 

Allegati

  • sofo sofo sofo sofo sofo sofo sofo.png
    sofo sofo sofo sofo sofo sofo sofo.png
    25 KB · Visite: 384
1° tp 2,5 anche questo ottimo titolo :clap:
 
Insg....

Che è Successo?

-10%....


Azz...

E' Da Uscire?
 
non me ne' voglia nessuno ma se' un giorno lascio questo thread il leader

incontrastato per me sarebbe trasparente fa' delle segnalazione di gioielli

per esempio oggi ha segnalato mvis è un titolo eccezionale è dopo vi dico perche' ora posto il grafico
 

Allegati

  • mvis mvis mvis mvis.png
    mvis mvis mvis mvis.png
    26,1 KB · Visite: 360
notate che ha fatto un minimo piu' basso di 4 anni fa' ma il macd ha una grossisima divergenza segno che tipo "movi" potrebbe invertire ed impennarsi
 
OSI & C,,,

come la vedete CIMT???
 
E' il grande Coffe che ha segnalato MVIS...
io non mi sento neppure lontanamente alla vostra altezza...
voi sapete fiutare la speculazione...io no...penso di cavarmela meglio nell'interpretazione grafica...
 
certo è una scommessa ma sono proprio questi i titoli che possono dare le piu' belle soddisfazioni

pero' questa volta non lo dico piu' a gasfin ( il re dei minimi) tanto l' altra volta non mi neanche risposto
 
onore allora a coffe l' altro socio onorario :bow: :bow: :bow:
 
PalmBeach ha scritto:
OSI & C,,,

come la vedete CIMT???


palm,,,io la vidi gia da due sedute addietro,,,pero ce l ipotetico incrocio al ribasso della 662 su 966,,,,che a me non piace
 
Mi distraggo un attimo ed FTGX rompe i 3,09... :angry:
:rolleyes:
Secondo voi ci sta un obiettivo intorno ai 4,30/4,50? :mmmm:

Bye!Y2K
:D :D :D
 
Ultima modifica:
premetto che e una ciofeca perche non fattura un tubo,,,
pero' e' intrigante,,,
PARS


Pharmos Agrees to Acquire Vela Pharmaceuticals Inc.

Expands Pipeline with Later-Stage Clinical Drug Candidates Including R-tofisopam, a Drug with Positive Phase 2 Data for the Treatment of Diarrhea-Predominant and Alternating-Type IBS

Broadens Management Team and Board with Accomplished Industry Leaders

Iselin NJ, March 15, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that it has entered into a definitive agreement to acquire Vela Pharmaceuticals Inc., a venture-capital backed, privately owned company specializing in the development of medicines related to diseases of the nervous system including disorders of the "brain-gut axis." The transaction includes an initial payment of $5.0 million in cash and the issuance of 11.5 million shares of Pharmos common stock for a combined value of approximately $29.7 million (based on Pharmos' recent $2.15 per share closing stock price). The transaction also includes the issuance of up to 8.0 million additional Pharmos shares contingent on achieving specific clinical milestones.

The transaction will create a combined company focused primarily on diseases of the nervous system and autoimmune disorders. Pharmos' assets include over $45 million in cash (based on Pharmos' cash on hand as of December 31, 2005) and a strong drug development pipeline. The most advanced drug in clinical development in the combined company's pipeline will be Vela's R-tofisopam, a promising and innovative new drug that has demonstrated positive Phase 2 data for the treatment of diarrhea-predominant and alternating-type irritable bowel syndrome (IBS). Overall, IBS accounts for approximately 12% of all visits to primary care physicians in the U.S. and is the second most common disease treated by gastroenterologists. In addition, IBS-associated health care costs are in the range of $20-$25 billion annually. Scientists at Vela believe R-tofisopam targets IBS symptoms by acting upon the "brain-gut axis" rather than 5-HT3 and 5-HT4 receptors found within the gastrointestinal (GI) tract. In addition, R-tofisopam has been found to have anti-inflammatory properties that are being evaluated preclinically.

The Pharmos clinical pipeline will also include cannabinor, a promising drug candidate for the treatment of pain, inflammation and autoimmune disease. Cannabinor successfully completed a Phase 1 trial in January 2006 and is scheduled to initiate a Phase 2a trial in the second quarter of 2006. The Pharmos combined preclinical pipeline will continue to be driven by its industry-leading cannabinoid type two (CB2) receptor agonist platform with additional leading cannabinoid type one (CB1) receptor and CB2 receptor agonists and antagonists showing promise for a variety of significant indications.

Haim Aviv, Ph.D., Chairman and CEO of Pharmos, said, "We are pleased to announce this significant acquisition that will provide Pharmos with a later clinical stage drug. Our criteria and process for screening were rigorous, and after reviewing numerous candidates, we believe that Vela is an excellent strategic and scientific fit for Pharmos. Specifically, the Vela pipeline extends our presence in the specialty nervous system arena and expands our CNS focus with additional disease targets. We believe potential FDA approvals of cannabinoid-based products in obesity will further highlight the emerging cannabinoid class of therapies and will serve to spotlight Pharmos as a leader in this exciting new area.

Dr. Aviv continued, "This acquisition also strengthens our management team and expands our expertise. We are delighted to welcome seasoned new members to the Pharmos board of directors who will bring exceptionally strong expertise in science, business, and management along with key Vela executives that will complement and strengthen our existing team. Finally, we believe that this transaction is a transforming event and a key platform to build shareholder value for Pharmos and will increase the versatility of our opportunities."

Alan Rubino, President and Chief Operating Officer of Pharmos, said, "Pharmos' acquisition of Vela is indeed a transforming event for our Company. This acquisition is a critical and important step as we execute our more aggressive and cohesive business strategy to transform Pharmos into a progressive specialty pharmaceutical company. With the addition of Vela, we accomplish the critical strategic goal of adding compelling pipeline assets that best leverage our core operational and scientific expertise. Pharmos will now have an expanded drug portfolio that includes later-stage, early-stage, and preclinical drug candidates that better complements our long-term presence in the nervous system arena.

Mr. Rubino added, "We are particularly pleased to add R-tofisopam, a promising drug for IBS with solid Phase 2 clinical data. The market for IBS drugs is very large and underserved. This disease is estimated to affect more than 35 million adults in the United States, or approximately 10-15% of the adult population, and current treatment options have significant deficiencies. We are impressed by the overall quality of safety and efficacy data from the Phase 2 trial and are encouraged by the existing and anticipated market potential for offering an effective drug for patients suffering from a syndrome that impairs the quality of life for so many people. Ultimately, we believe Vela's lead product candidate, R-tofisopam, has significant therapeutic promise with the potential to materially expand the market for IBS therapies and represents large volume revenue potential."

Mr. Rubino emphasized, "Pharmos will continue to advance its targeted business development program that includes selective product in-licensing/out-licensing along with a special focus on developing targeted strategic alliances and scientific collaborations."

Tony Evnin, Ph.D., Managing General Partner of Venrock Associates, added, "We are delighted to integrate into Pharmos through this transaction and excited about participating in the future of the Company. The resources and infrastructure of Pharmos will expedite the clinical progression of R-tofisopam as it moves toward commercialization. We are committed to making Pharmos a significant player in the field of nervous system related disorders and enhancing its leadership in discovery and development of cannabinoid therapies."

Details of the Transaction
Under terms of the transaction, Pharmos will pay $5.0 million in cash and will issue 11.5 million shares of Pharmos Corporation common stock at the closing in exchange for all outstanding Vela securities. Vela shareholders will also receive up to an additional 8.0 million Pharmos shares contingent upon the achievement of specific performance-based milestones related to the development of R-tofisopam and comprised of 4.0 million shares upon successful completion of a Phase 2b clinical trial and 4.0 million shares upon the filing of a New Drug Application with the U.S. Food and Drug Administration. As of December 31, 2005, Pharmos had 19.1 million shares outstanding.

Following the closing of the transaction, three members of the Vela Board of Directors will join the Pharmos Board of Directors. These new members will be Tony Evnin, Ph.D., of Venrock Associates, Chuck Newhall III of New Enterprise Associates, Inc., and Srini Akkaraju, M.D., Ph.D., of J.P. Morgan Partners, LLC. In connection with the transaction, one existing Pharmos Director will step down from the Pharmos Board.

Steven M. Leventer, Ph.D., the head of research and development for Vela, will join Pharmos along with a team of three scientific professionals who are key members of the project team dedicated to the R-tofisopam clinical development/NDA program.

RBC Capital Markets Corporation and RBC's Israeli affiliate, Tamir Fishman & Co., served as financial advisors, and Eilenberg & Krause LLP served as legal advisor to Pharmos Corporation. Cowen & Co., LLC served as financial advisor and Drinker Biddle & Reath LLP served as legal advisor to Vela Pharmaceuticals Inc
 
Ultima modifica:
y2k ha scritto:
Mi distraggo un attimo ed FTGX rompe i 3,09... :angry:
:rolleyes:
Secondo voi ci sta un obiettivo intorno ai 4,30/4,50? :mmmm:

Bye!Y2K
:D :D :D
Non ho fatto in tempo a parlare che ripiomba giu... :mmmm:
ci sarà mica una spia... tra di noi.. :D

Comunque un close sopra 3,09 secondo me è interessante.. :)

entrato, un poco, a 3,17.. rivedrò in chiusura.


Bye!Y2K
:D :D :D
 
y2k ha scritto:
Non ho fatto in tempo a parlare che ripiomba giu... :mmmm:
ci sarà mica una spia... tra di noi.. :D

Comunque un close sopra 3,09 secondo me è interessante.. :)

entrato, un poco, a 3,17.. rivedrò in chiusura.


Bye!Y2K
:D :D :D



vai tranquillo y2 è un ottimo titolo è andra' senza problemi a target di 4,8 quindi oltre +50%
 
Buona sera a tutti!
Cosa ne pensate di WAVX?
Inizia a diventare interessante? :confused:
 
Indietro